Advertisement
AZN vs BIIB
Which Stock Would AI Choose? AstraZeneca (AZN) vs. Biogen (BIIB) Stock Comparison
Key Takeaways
- AstraZeneca (AZN) reported strong first-quarter revenue growth driven by oncology and rare disease drugs, reaffirming full-year guidance.
- Biogen (BIIB) faces upcoming quarterly earnings with analyst upgrades highlighting pipeline catalysts, amid expectations of revenue decline.
- AZN boasts a market capitalization (market cap) of approximately $289 billion, dwarfing BIIB's $27 billion, reflecting greater scale and stability.
- Year-to-date (YTD), both stocks show modest gains, with BIIB at around 4% and AZN between 2-6%, but recent weeks saw declines of about 4-7%.
- AZN's price-to-earnings (PE) ratio stands at 28.6, higher than BIIB's 20.9, indicating differing growth expectations.
- Analyst sentiment favors both, with recent UBS upgrades for BIIB to a $225 target, while AZN maintains strong buy ratings around $224.
Introduction
AstraZeneca (AZN) and Biogen (BIIB) represent key players in the biopharmaceutical sector, with AZN offering diversified global exposure and BIIB focusing on neurology innovations. This stock comparison analyzes their recent performance, business drivers, and market positioning amid evolving healthcare demands and economic pressures. Traders seeking sector rotation opportunities or long-term investors evaluating stability versus growth potential will find value in understanding their relative strengths, momentum shifts, and risk profiles in the current market environment.
AZN Overview and Recent Performance
AstraZeneca PLC (AZN) is a multinational pharmaceutical giant specializing in oncology, rare diseases, and respiratory therapies. In recent market activity, the stock has traded around $187, within a 52-week range of $132 to $213. Shares experienced a pullback of about 7% over the past month but remain up modestly year-to-date. Positive sentiment stems from robust quarterly results, with revenue surpassing expectations at $15.3 billion, fueled by strong demand for cancer and rare disease treatments. The company reaffirmed its annual growth outlook, bolstering confidence despite broader sector volatility and recent price dips linked to market rotations.
BIIB Overview and Recent Performance
Biogen Inc. (BIIB) concentrates on neurological disorders, particularly multiple sclerosis (MS) therapies, alongside emerging Alzheimer's and gene therapy pipelines. Trading near $183 in a 52-week span from $115 to $202, the stock has seen a roughly 4% monthly decline but holds YTD gains around 4%. Recent upgrades from analysts like UBS, citing pipeline catalysts into 2027, have lifted sentiment ahead of quarterly earnings, despite forecasts of revenue contraction from legacy MS franchise pressures. New launches and partnerships, such as in multiple myeloma, provide counterbalance to challenges in core areas.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top 25 AI trading bots selected from over 350 total bots, curated for optimal performance in prevailing market conditions. These bots trade thousands of tickers across diverse strategies, including momentum, sector rotation, day trading, and swing approaches, with reported annualized returns reaching up to 227%, win rates of 70-80%, and profit factors exceeding 2.0 in top performers. Stats vary by bot—some achieve 73% success rates on trend analysis, others deliver 112% returns in tech sectors or 77% in industrials—highlighting adaptability to volatility, growth themes, and timeframes from intraday to longer holds. Explore these high-performing AI tools to enhance your trading edge in dynamic markets like biotech.
Head-to-Head Comparison
AZN and BIIB operate in biopharma but diverge in scale and focus: AZN's diversified model spans oncology and global markets for steady growth, while BIIB's neurology-centric biotech profile offers higher upside from pipeline breakthroughs but greater exposure to clinical risks. Recent momentum shows AZN buoyed by earnings beats versus BIIB's pre-earnings anticipation. Risk factors include BIIB's smaller cap implying volatility, contrasted by AZN's resilience. Sector sentiment favors oncology drivers for AZN, while BIIB benefits from neuro innovation trade-offs.
Tickeron AI Verdict
Tickeron’s AI models currently favor AZN over BIIB based on superior trend consistency from recent earnings strength, larger scale for stability, and positive relative positioning in oncology growth. While BIIB shows pipeline potential, its higher volatility and earnings uncertainty temper short-term appeal. This probabilistic edge aligns with observable catalysts rather than guarantees.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZN is a Hold and BIIB is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZN’s FA Score shows that 2 FA rating(s) are green whileBIIB’s FA Score has 2 green FA rating(s).
- AZN’s FA Score: 2 green, 3 red.
- BIIB’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZN’s TA Score shows that 4 TA indicator(s) are bullish while BIIB’s TA Score has 3 bullish TA indicator(s).
- AZN’s TA Score: 4 bullish, 3 bearish.
- BIIB’s TA Score: 3 bullish, 3 bearish.
Price Growth
AZN (@Pharmaceuticals: Major) experienced а -0.47% price change this week, while BIIB (@Pharmaceuticals: Major) price change was +0.54% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.28%. For the same industry, the average monthly price growth was +6.74%, and the average quarterly price growth was +2.91%.
Reported Earning Dates
AZN is expected to report earnings on Jul 27, 2026.
BIIB is expected to report earnings on Jul 16, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+3.28% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AZN | BIIB | AZN / BIIB | |
| Capitalization | 272B | 29.5B | 922% |
| EBITDA | 20.1B | 2.7B | 745% |
| Gain YTD | 91.918 | 13.478 | 682% |
| P/E Ratio | 26.57 | 21.47 | 124% |
| Revenue | 60.4B | 9.94B | 608% |
| Total Cash | 7.68B | 4.28B | 179% |
| Total Debt | 33.9B | 6.56B | 517% |
AZN | BIIB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 63 | 62 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 12 Undervalued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 7 | 100 | |
SMR RATING 1..100 | 41 | 79 | |
PRICE GROWTH RATING 1..100 | 39 | 24 | |
P/E GROWTH RATING 1..100 | 58 | 13 | |
SEASONALITY SCORE 1..100 | 44 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AZN's Valuation (12) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (80) in the Biotechnology industry. This means that AZN’s stock grew significantly faster than BIIB’s over the last 12 months.
AZN's Profit vs Risk Rating (7) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (100) in the Biotechnology industry. This means that AZN’s stock grew significantly faster than BIIB’s over the last 12 months.
AZN's SMR Rating (41) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (79) in the Biotechnology industry. This means that AZN’s stock grew somewhat faster than BIIB’s over the last 12 months.
BIIB's Price Growth Rating (24) in the Biotechnology industry is in the same range as AZN (39) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to AZN’s over the last 12 months.
BIIB's P/E Growth Rating (13) in the Biotechnology industry is somewhat better than the same rating for AZN (58) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew somewhat faster than AZN’s over the last 12 months.
| AZN | BIIB | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 50% | N/A |
| Stochastic ODDS (%) | 2 days ago 60% | 2 days ago 72% |
| Momentum ODDS (%) | 2 days ago 56% | 2 days ago 51% |
| MACD ODDS (%) | 2 days ago 41% | 2 days ago 54% |
| TrendWeek ODDS (%) | 2 days ago 45% | 2 days ago 73% |
| TrendMonth ODDS (%) | 2 days ago 43% | 2 days ago 59% |
| Advances ODDS (%) | 19 days ago 57% | 12 days ago 57% |
| Declines ODDS (%) | 6 days ago 45% | 8 days ago 71% |
| BollingerBands ODDS (%) | 2 days ago 61% | N/A |
| Aroon ODDS (%) | N/A | 2 days ago 68% |
Advertisement
AZN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AZN has been loosely correlated with BIIB. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AZN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AZN | 1D Price Change % | ||
|---|---|---|---|---|
| AZN | 100% | +0.86% | ||
| BIIB - AZN | 48% Loosely correlated | +1.59% | ||
| LLY - AZN | 44% Loosely correlated | +0.32% | ||
| GILD - AZN | 39% Loosely correlated | +0.90% | ||
| MRK - AZN | 30% Poorly correlated | +1.41% | ||
| NVS - AZN | 28% Poorly correlated | +1.26% | ||
More | ||||